GlassScriptPhysician profile
Kevin D Waldo
NPI 1356018543
$7,861.03
in general payments reported to CMS, 2019-2025
30 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,855 · 2023: $1,964 · 2024: $2,300 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,422.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,023.04 | 2021-2025 | |
| Janssen Biotech, INC. | $881.37 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $834.75 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $371.94 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $363.50 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.16 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $282.12 | 2022-2025 | |
| Gilead Sciences, INC. | $252.18 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $244.72 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $217.31 | 2023-2025 | Sucraid, Sucraid |
| Enterra Medical, INC. | $213.27 | 2023 | |
| Dynavax Technologies Corporation | $138.25 | 2022 | |
| Merck Sharp & Dohme LLC | $102.43 | 2022-2023 | Dificid |
| Lilly USA, LLC | $84.46 | 2023-2024 | Omvoh |
| Madrigal Pharmaceuticals | $66.24 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $64.62 | 2022-2024 | Linzess |
| Vivus LLC | $62.36 | 2024-2025 | Pancreaze |
| Aimmune Therapeutics, INC. | $48.42 | 2024 | |
| Ardelyx, INC. | $45.41 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $45.23 | 2022-2025 | Suflave, Sutab |
| Sandoz INC. | $36.94 | 2024 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $33.43 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $25.73 | 2023 | Rebyota |
| Azurity Pharmaceuticals, INC. | $22.92 | 2025 | Sutab |
| Daiichi Sankyo INC. | $22.18 | 2022 | |
| Pfizer INC. | $17.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $16.89 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $16.50 | 2022 | |
| Mannkind Corporation | $14.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Waldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.